Organogenesis (ORGO) Financials

$4.32 -0.01 (-0.23%)

Closing price 04:00 PM Eastern

Extended Trading

$4.56 +0.23 (+5.44%)

As of 07:24 PM Eastern

Annual Income Statements for Organogenesis

This table shows Organogenesis' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	16	4.95	-0.94
Consolidated Net Income / (Loss)	16	4.95	0.86
Net Income / (Loss) Continuing Operations	16	4.95	0.86
Total Pre-Tax Income	20	10	-2.81
Total Operating Income	22	13	-1.28
Total Gross Profit	346	327	366
Total Revenue	451	433	482
Operating Revenue	451	433	482
Total Cost of Revenue	105	106	116
Operating Cost of Revenue	105	106	116
Total Operating Expenses	324	314	368
Selling, General & Admin Expense	284	270	295
Research & Development Expense	40	44	50
Other Operating Expenses / (Income)	0.00	0.00	3.96
Impairment Charge	0.00	0.00	19
Total Other Income / (Expense), net	-2.02	-2.13	-1.52
Interest Expense	2.01	2.19	1.54
Other Income / (Expense), net	-0.01	0.06	0.02
Income Tax Expense	4.75	5.45	-3.67
Preferred Stock Dividends Declared	0.00	0.00	1.80
Basic Earnings per Share	$0.12	$0.04	($0.01)
Weighted Average Basic Shares Outstanding	130.07M	131.23M	131.67M
Diluted Earnings per Share	$0.12	$0.04	($0.01)
Weighted Average Diluted Shares Outstanding	132.38M	132.75M	131.67M
Weighted Average Basic & Diluted Shares Outstanding	131.18M	131.96M	126.83M

This table shows Organogenesis' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	0.22	7.49	-2.97	5.32	3.17	-0.57	-2.10	-17	12	5.88
Consolidated Net Income / (Loss)	0.22	7.49	-2.97	5.32	3.17	-0.57	-2.10	-17	12	7.67
Net Income / (Loss) Continuing Operations	0.22	7.49	-2.97	5.32	3.17	-0.57	-2.10	-17	12	7.67
Total Pre-Tax Income	1.21	8.75	-4.63	9.18	7.64	-1.80	-4.34	-15	5.82	10
Total Operating Income	1.78	8.72	-4.00	9.75	8.05	-1.27	-3.85	-14	6.24	10
Total Gross Profit	91	88	81	91	83	72	81	101	88	96
Total Revenue	117	116	108	117	109	100	110	130	115	127
Operating Revenue	117	116	108	117	109	100	110	130	115	127
Total Cost of Revenue	26	27	27	26	26	28	29	29	27	31
Operating Cost of Revenue	26	27	27	26	26	28	29	29	27	31
Total Operating Expenses	89	80	85	81	75	73	85	115	82	85
Selling, General & Admin Expense	79	68	74	70	64	61	72	77	72	74
Research & Development Expense	9.58	11	11	11	10	12	13	16	10	12
Total Other Income / (Expense), net	-0.57	0.03	-0.63	-0.57	-0.41	-0.53	-0.49	-0.65	-0.42	0.03
Interest Expense	0.57	-0.03	0.65	0.59	0.44	0.50	0.51	0.62	0.47	-0.06
Other Income / (Expense), net	0.01	-	0.02	0.03	0.03	-0.03	0.02	-0.03	0.05	-0.03
Income Tax Expense	1.00	1.27	-1.66	3.86	4.47	-1.23	-2.24	2.50	-6.51	2.58
Basic Earnings per Share	$0.00	$0.06	($0.02)	$0.04	$0.02	-	($0.02)	($0.13)	$0.09	$0.05
Weighted Average Basic Shares Outstanding	130.90M	130.07M	131.08M	131.29M	131.31M	131.23M	131.86M	132.57M	132.58M	131.67M
Diluted Earnings per Share	$0.00	$0.06	($0.02)	$0.04	$0.02	-	($0.02)	($0.13)	$0.09	$0.05
Weighted Average Diluted Shares Outstanding	132.23M	132.38M	131.08M	133.07M	133.42M	132.75M	131.86M	132.57M	133.93M	131.67M
Weighted Average Basic & Diluted Shares Outstanding	130.92M	131.18M	131.26M	131.31M	132.04M	131.96M	132.57M	132.58M	132.58M	126.83M

This table details how cash moves in and out of Organogenesis' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Change in Cash & Equivalents	-11	1.05	32
Net Cash From Operating Activities	25	31	14
Net Cash From Continuing Operating Activities	25	31	14
Net Income / (Loss) Continuing Operations	16	4.95	0.86
Consolidated Net Income / (Loss)	16	4.95	0.86
Depreciation Expense	5.85	10	14
Amortization Expense	12	4.92	3.40
Non-Cash Adjustments To Reconcile Net Income	16	18	42
Changes in Operating Assets and Liabilities, net	-25	-7.62	-46
Net Cash From Investing Activities	-34	-24	-10
Net Cash From Continuing Investing Activities	-34	-24	-10
Purchase of Property, Plant & Equipment	-34	-24	-10
Net Cash From Financing Activities	-2.20	-5.51	28
Net Cash From Continuing Financing Activities	-2.20	-5.51	28
Repayment of Debt	-3.01	-5.17	-68
Repurchase of Common Equity	0.00	0.00	-25
Issuance of Preferred Equity	0.00	0.00	121
Other Financing Activities, net	0.81	-0.33	0.07
Cash Interest Paid	2.65	5.44	4.97
Cash Income Taxes Paid	1.20	3.05	6.97

This table details how cash moves in and out of Organogenesis' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-4.92	-4.73	-14	0.09	9.32	5.51	-15	1.13	4.45	41
Net Cash From Operating Activities	5.45	7.80	-5.08	8.65	17	11	-10	4.74	8.70	11
Net Cash From Continuing Operating Activities	5.45	7.80	-5.08	8.65	17	11	-10	4.74	8.70	11
Net Income / (Loss) Continuing Operations	0.22	7.49	-2.97	5.32	3.17	-0.57	-2.10	-17	12	7.67
Consolidated Net Income / (Loss)	0.22	7.49	-2.97	5.32	3.17	-0.57	-2.10	-17	12	7.67
Depreciation Expense	1.46	1.51	2.69	2.23	2.54	2.98	3.07	3.37	3.57	3.62
Amortization Expense	1.22	8.52	1.23	1.23	1.23	1.23	0.90	0.83	0.83	0.83
Non-Cash Adjustments To Reconcile Net Income	5.87	-2.18	3.67	4.43	4.67	5.45	6.47	27	4.66	3.61
Changes in Operating Assets and Liabilities, net	-3.31	-7.54	-9.71	-4.56	5.13	1.52	-19	-9.54	-13	-4.80
Net Cash From Investing Activities	-10	-11	-7.56	-7.50	-5.98	-3.32	-2.22	-1.88	-2.57	-3.36
Net Cash From Continuing Investing Activities	-10	-11	-7.56	-7.50	-5.98	-3.32	-2.22	-1.88	-2.57	-3.36
Purchase of Property, Plant & Equipment	-10	-11	-7.56	-7.50	-5.98	-3.32	-2.22	-1.88	-2.57	-3.36
Net Cash From Financing Activities	0.03	-1.88	-1.24	-1.05	-1.44	-1.78	-2.61	-1.73	-1.68	34
Net Cash From Continuing Financing Activities	0.03	-1.88	-1.24	-1.05	-1.44	-1.78	-2.61	-1.73	-1.68	34
Repayment of Debt	-	-1.88	-0.94	-1.02	-1.44	-1.78	-1.67	-1.67	-1.68	-63
Other Financing Activities, net	0.03	-	-0.30	-0.03	-0.00	0.00	-0.94	-0.05	0.01	1.06
Cash Interest Paid	0.75	0.86	1.27	1.34	1.29	1.54	1.38	1.37	1.36	0.87
Cash Income Taxes Paid	-	0.23	0.13	2.89	-0.00	0.03	0.04	4.76	0.70	1.47

This table presents Organogenesis' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Total Assets	449	460	498
Total Current Assets	223	225	286
Cash & Equivalents	102	104	136
Restricted Cash	0.81	0.50	0.58
Accounts Receivable	89	82	110
Inventories, net	25	28	26
Prepaid Expenses	5.09	10	14
Plant, Property, & Equipment, net	102	116	89
Total Noncurrent Assets	124	119	123
Goodwill	29	29	29
Intangible Assets	21	16	12
Noncurrent Deferred & Refundable Income Taxes	30	28	39
Other Noncurrent Operating Assets	45	46	42
Total Liabilities & Shareholders' Equity	449	460	498
Total Liabilities	184	181	113
Total Current Liabilities	75	81	77
Short-Term Debt	4.54	19	0.00
Accounts Payable	32	31	29
Accrued Expenses	26	30	39
Other Current Liabilities	12	1.08	9.11
Total Noncurrent Liabilities	109	101	35
Long-Term Debt	66	61	0.00
Capital Lease Obligations	0.00	27	0.72
Other Noncurrent Operating Liabilities	42	13	34
Commitments & Contingencies	0.00	0.00	0.00
Redeemable Noncontrolling Interest	-	0.00	122
Total Equity & Noncontrolling Interests	266	279	263
Total Preferred & Common Equity	266	279	263
Preferred Stock	0.00	0.00	0.00
Total Common Equity	266	279	263
Common Stock	311	320	303
Retained Earnings	-45	-41	-40

This table presents Organogenesis' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	457	446	450	463	458	443	446
Total Current Assets	231	217	216	226	227	234	239
Cash & Equivalents	107	89	89	98	89	90	94
Restricted Cash	0.77	0.72	0.59	0.60	0.72	0.58	0.59
Accounts Receivable	93	92	94	89	96	106	101
Inventories, net	25	26	25	28	28	27	27
Prepaid Expenses	4.71	9.85	7.95	9.57	14	11	15
Plant, Property, & Equipment, net	97	107	112	118	114	90	90
Total Noncurrent Assets	130	123	122	120	117	119	118
Goodwill	29	29	29	29	29	29	29
Intangible Assets	22	20	18	17	15	14	13
Noncurrent Deferred & Refundable Income Taxes	32	30	30	30	28	34	36
Other Noncurrent Operating Assets	47	44	45	44	45	42	40
Total Liabilities & Shareholders' Equity	457	446	450	463	458	443	446
Total Liabilities	201	182	179	186	180	180	168
Total Current Liabilities	89	76	73	81	83	86	77
Short-Term Debt	17	17	18	5.48	5.49	17	16
Accounts Payable	38	30	27	27	23	29	24
Accrued Expenses	34	29	28	35	40	38	36
Other Current Liabilities	0.00	0.00	0.21	14	14	1.13	1.15
Total Noncurrent Liabilities	112	106	106	104	98	94	90
Long-Term Debt	68	65	63	62	59	58	56
Capital Lease Obligations	43	40	41	2.17	1.60	25	24
Other Noncurrent Operating Liabilities	1.09	1.15	1.19	40	37	11	11
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	256	264	271	277	278	264	279
Total Preferred & Common Equity	256	264	271	277	278	264	279
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	256	264	271	277	278	264	279
Common Stock	309	313	315	317	321	324	326
Retained Earnings	-53	-49	-44	-40	-43	-60	-48

This table displays calculated financial ratios and metrics derived from Organogenesis' official financial filings.

Metric	2022	2023	2024
Growth Metrics	-	-	-
Revenue Growth	-3.52%	-3.94%	11.29%
EBITDA Growth	-54.63%	-30.69%	-43.60%
EBIT Growth	-69.13%	-43.56%	-110.04%
NOPAT Growth	-84.16%	-65.11%	-115.07%
Net Income Growth	-83.51%	-68.16%	-82.59%
EPS Growth	-82.86%	-66.67%	-125.00%
Operating Cash Flow Growth	-59.89%	24.37%	-54.04%
Free Cash Flow Firm Growth	504.07%	-196.94%	171.89%
Invested Capital Growth	-9.95%	20.37%	-10.96%
Revenue Q/Q Growth	-2.66%	-3.53%	5.93%
EBITDA Q/Q Growth	-12.63%	-36.05%	30.03%
EBIT Q/Q Growth	-33.13%	-44.11%	90.09%
NOPAT Q/Q Growth	-73.60%	-57.35%	89.95%
Net Income Q/Q Growth	-73.69%	-61.96%	111.67%
EPS Q/Q Growth	-73.33%	-60.00%	83.33%
Operating Cash Flow Q/Q Growth	-28.99%	10.01%	2.33%
Free Cash Flow Firm Q/Q Growth	202.81%	-198.38%	173.23%
Invested Capital Q/Q Growth	-15.54%	13.25%	-10.64%
Profitability Metrics	-	-	-
Gross Margin	76.71%	75.42%	75.99%
EBITDA Margin	8.94%	6.45%	3.27%
Operating Margin	4.95%	2.89%	-0.27%
EBIT Margin	4.94%	2.90%	-0.26%
Profit (Net Income) Margin	3.44%	1.14%	0.18%
Tax Burden Percent	76.58%	47.58%	-30.67%
Interest Burden Percent	90.99%	82.59%	222.25%
Effective Tax Rate	23.42%	52.42%	0.00%
Return on Invested Capital (ROIC)	6.94%	2.32%	-0.34%
ROIC Less NNEP Spread (ROIC-NNEP)	27.66%	8.97%	-2.97%
Return on Net Nonoperating Assets (RNNOA)	-0.82%	-0.50%	0.60%
Return on Equity (ROE)	6.13%	1.82%	0.26%
Cash Return on Invested Capital (CROIC)	17.41%	-16.17%	11.26%
Operating Return on Assets (OROA)	4.99%	2.77%	-0.26%
Return on Assets (ROA)	3.48%	1.09%	0.18%
Return on Common Equity (ROCE)	6.13%	1.82%	0.21%
Return on Equity Simple (ROE_SIMPLE)	5.85%	1.77%	0.33%
Net Operating Profit after Tax (NOPAT)	17	5.96	-0.90
NOPAT Margin	3.79%	1.38%	-0.19%
Net Nonoperating Expense Percent (NNEP)	-20.72%	-6.65%	2.64%
Return On Investment Capital (ROIC_SIMPLE)	5.08%	1.55%	-0.34%
Cost of Revenue to Revenue	23.29%	24.58%	24.01%
SG&A Expenses to Revenue	62.94%	62.28%	61.10%
R&D to Revenue	8.82%	10.25%	10.43%
Operating Expenses to Revenue	71.76%	72.52%	76.26%
Earnings before Interest and Taxes (EBIT)	22	13	-1.26
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	40	28	16
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.33	1.94	1.61
Price to Tangible Book Value (P/TBV)	1.63	2.31	1.91
Price to Revenue (P/Rev)	0.78	1.25	0.88
Price to Earnings (P/E)	22.67	109.21	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	4.41%	0.92%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.37	1.93	1.65
Enterprise Value to Revenue (EV/Rev)	0.71	1.25	0.85
Enterprise Value to EBITDA (EV/EBITDA)	7.93	19.39	26.09
Enterprise Value to EBIT (EV/EBIT)	14.34	43.08	0.00
Enterprise Value to NOPAT (EV/NOPAT)	18.71	90.94	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	12.86	17.53	28.94
Enterprise Value to Free Cash Flow (EV/FCFF)	7.46	0.00	13.77
Leverage & Solvency	-	-	-
Debt to Equity	0.27	0.38	0.00
Long-Term Debt to Equity	0.25	0.31	0.00
Financial Leverage	-0.03	-0.06	-0.20
Leverage Ratio	1.76	1.67	1.44
Compound Leverage Factor	1.60	1.38	3.21
Debt to Total Capital	21.03%	27.62%	0.19%
Short-Term Debt to Total Capital	1.35%	4.84%	0.00%
Long-Term Debt to Total Capital	19.69%	22.78%	0.19%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	31.71%
Common Equity to Total Capital	78.97%	72.38%	68.10%
Debt to EBITDA	1.76	3.80	0.05
Net Debt to EBITDA	-0.81	0.07	-8.59
Long-Term Debt to EBITDA	1.64	3.14	0.05
Debt to NOPAT	4.14	17.84	-0.80
Net Debt to NOPAT	-1.90	0.33	150.80
Long-Term Debt to NOPAT	3.88	14.71	-0.80
Altman Z-Score	2.57	3.07	3.61
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	18.44%
Liquidity Ratios	-	-	-
Current Ratio	2.97	2.80	3.69
Quick Ratio	2.56	2.31	3.17
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	43	-42	30
Operating Cash Flow to CapEx	73.33%	126.90%	141.63%
Free Cash Flow to Firm to Interest Expense	21.33	-18.96	19.34
Operating Cash Flow to Interest Expense	12.37	14.12	9.20
Operating Cash Flow Less CapEx to Interest Expense	-4.50	2.99	2.70
Efficiency Ratios	-	-	-
Asset Turnover	1.01	0.95	1.01
Accounts Receivable Turnover	5.25	5.05	5.02
Inventory Turnover	4.22	4.02	4.25
Fixed Asset Turnover	4.97	3.96	4.69
Accounts Payable Turnover	3.41	3.38	3.88
Days Sales Outstanding (DSO)	69.58	72.24	72.64
Days Inventory Outstanding (DIO)	86.55	90.90	85.89
Days Payable Outstanding (DPO)	107.17	108.07	94.03
Cash Conversion Cycle (CCC)	48.96	55.07	64.50
Capital & Investment Metrics	-	-	-
Invested Capital	233	281	250
Invested Capital Turnover	1.83	1.69	1.82
Increase / (Decrease) in Invested Capital	-26	47	-31
Enterprise Value (EV)	320	542	411
Market Capitalization	352	540	424
Book Value per Share	$2.03	$2.11	$1.98
Tangible Book Value per Share	$1.65	$1.77	$1.67
Total Capital	336	385	386
Total Debt	71	106	0.72
Total Long-Term Debt	66	88	0.72
Net Debt	-33	1.98	-135
Capital Expenditures (CapEx)	34	24	10
Debt-free, Cash-free Net Working Capital (DFCFNWC)	49	59	72
Debt-free Net Working Capital (DFNWC)	152	163	208
Net Working Capital (NWC)	148	145	208
Net Nonoperating Expense (NNE)	1.55	1.01	-1.76
Net Nonoperating Obligations (NNO)	-33	1.98	-135
Total Depreciation and Amortization (D&A)	18	15	17
Debt-free, Cash-free Net Working Capital to Revenue	10.83%	13.58%	15.00%
Debt-free Net Working Capital to Revenue	33.74%	37.67%	43.25%
Net Working Capital to Revenue	32.73%	33.37%	43.25%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.04	($0.01)
Adjusted Weighted Average Basic Shares Outstanding	0.00	131.23M	131.67M
Adjusted Diluted Earnings per Share	$0.00	$0.04	($0.01)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	132.75M	131.67M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	131.96M	126.83M
Normalized Net Operating Profit after Tax (NOPAT)	17	8.77	12
Normalized NOPAT Margin	3.79%	2.02%	2.55%
Pre Tax Income Margin	4.50%	2.40%	-0.58%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	11.10	5.75	-0.82
NOPAT to Interest Expense	8.50	2.72	-0.58
EBIT Less CapEx to Interest Expense	-5.78	-5.38	-7.32
NOPAT Less CapEx to Interest Expense	-8.37	-8.40	-7.08
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	2,959.23%

This table displays calculated financial ratios and metrics derived from Organogenesis' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	2.73%	-9.65%	10.84%	-3.36%	-7.13%	-13.73%	2.17%	11.01%	6.12%	27.10%
EBITDA Growth	-78.74%	-23.65%	-101.26%	3.23%	165.78%	-84.44%	366.67%	-173.47%	-9.75%	401.75%
EBIT Growth	-89.02%	-55.84%	-3,007.81%	-17.97%	352.97%	-114.84%	3.75%	-242.43%	-22.11%	887.64%
NOPAT Growth	-98.01%	-86.02%	-3,025.78%	-39.52%	957.81%	-111.92%	3.72%	-272.30%	295.96%	960.92%
Net Income Growth	-98.29%	-85.32%	-225.19%	-39.20%	1,373.02%	-107.60%	29.27%	-420.60%	289.36%	1,448.51%
EPS Growth	-100.00%	-84.62%	-100.00%	-42.86%	0.00%	0.00%	0.00%	-425.00%	350.00%	0.00%
Operating Cash Flow Growth	-80.42%	-56.54%	-459.82%	-15.19%	206.88%	36.08%	-100.16%	-45.20%	-48.04%	3.04%
Free Cash Flow Firm Growth	-913.57%	151.01%	65.87%	67.09%	129.77%	-245.65%	212.06%	175.00%	-158.95%	179.38%
Invested Capital Growth	62.70%	-9.95%	12.02%	12.86%	-10.23%	20.37%	-13.99%	-10.35%	12.85%	-10.96%
Revenue Q/Q Growth	-3.74%	-1.15%	-6.82%	8.99%	-7.49%	-8.18%	10.36%	18.42%	-11.56%	9.97%
EBITDA Q/Q Growth	-65.20%	320.54%	-100.29%	24,600.00%	-10.40%	-75.38%	-98.69%	-6,850.00%	210.06%	36.86%
EBIT Q/Q Growth	-85.03%	388.68%	-145.63%	345.68%	-17.31%	-116.01%	-195.90%	-263.54%	145.22%	61.93%
NOPAT Q/Q Growth	-96.62%	2,262.37%	-137.57%	301.51%	-40.85%	-126.61%	-203.55%	-260.64%	235.93%	-42.14%
Net Income Q/Q Growth	-97.54%	3,381.86%	-139.66%	279.05%	-40.43%	-117.97%	-269.07%	-711.57%	172.35%	-37.77%
EPS Q/Q Growth	-100.00%	0.00%	-133.33%	300.00%	-50.00%	0.00%	0.00%	-550.00%	169.23%	-44.44%
Operating Cash Flow Q/Q Growth	-46.51%	43.04%	-165.09%	270.30%	93.55%	-36.57%	-195.75%	146.62%	83.52%	25.78%
Free Cash Flow Firm Q/Q Growth	-20.32%	131.32%	-204.23%	16.21%	208.85%	-253.21%	360.11%	-43.91%	-185.55%	306.31%
Invested Capital Q/Q Growth	2.40%	-15.54%	27.23%	2.56%	-18.55%	13.25%	3.23%	6.90%	2.53%	-10.64%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	77.60%	76.53%	75.28%	77.57%	76.24%	72.13%	73.91%	77.58%	76.73%	75.48%
EBITDA Margin	3.82%	16.24%	-0.05%	11.28%	10.92%	2.93%	0.13%	-7.46%	9.29%	11.56%
Operating Margin	1.52%	7.55%	-3.72%	8.31%	7.42%	-1.27%	-3.50%	-10.67%	5.42%	8.07%
EBIT Margin	1.53%	7.55%	-3.70%	8.33%	7.45%	-1.30%	-3.48%	-10.69%	5.46%	8.05%
Profit (Net Income) Margin	0.18%	6.48%	-2.76%	4.53%	2.92%	-0.57%	-1.91%	-13.09%	10.71%	6.06%
Tax Burden Percent	17.74%	85.52%	64.17%	57.91%	41.47%	31.66%	48.35%	117.21%	211.76%	74.84%
Interest Burden Percent	67.94%	100.41%	116.31%	93.92%	94.51%	138.87%	113.42%	104.45%	92.52%	100.60%
Effective Tax Rate	82.26%	14.48%	0.00%	42.09%	58.53%	0.00%	0.00%	0.00%	-111.76%	25.16%
Return on Invested Capital (ROIC)	0.56%	11.83%	-4.28%	7.67%	5.27%	-1.50%	-3.87%	-11.61%	19.80%	10.97%
ROIC Less NNEP Spread (ROIC-NNEP)	-95.23%	11.42%	-4.89%	6.31%	8.94%	-3.59%	7.99%	-46.29%	26.15%	10.93%
Return on Net Nonoperating Assets (RNNOA)	-0.04%	-0.34%	-0.53%	0.58%	-0.16%	0.20%	0.15%	-3.65%	-1.32%	-2.20%
Return on Equity (ROE)	0.52%	11.49%	-4.80%	8.25%	5.12%	-1.30%	-3.72%	-15.26%	18.49%	8.77%
Cash Return on Invested Capital (CROIC)	-18.70%	17.41%	-5.98%	-8.16%	16.12%	-16.17%	17.54%	8.25%	-15.46%	11.26%
Operating Return on Assets (OROA)	1.71%	7.62%	-3.87%	8.40%	7.27%	-1.24%	-3.35%	-10.73%	5.47%	8.10%
Return on Assets (ROA)	0.21%	6.55%	-2.88%	4.57%	2.85%	-0.54%	-1.84%	-13.13%	10.72%	6.10%
Return on Common Equity (ROCE)	0.52%	11.49%	-4.80%	8.25%	5.12%	-1.30%	-3.72%	-15.26%	18.49%	7.16%
Return on Equity Simple (ROE_SIMPLE)	23.03%	0.00%	5.11%	3.70%	4.70%	0.00%	2.09%	-6.28%	-2.65%	0.00%
Net Operating Profit after Tax (NOPAT)	0.32	7.46	-2.80	5.64	3.34	-0.89	-2.70	-9.72	13	7.65
NOPAT Margin	0.27%	6.45%	-2.60%	4.81%	3.08%	-0.89%	-2.45%	-7.47%	11.48%	6.04%
Net Nonoperating Expense Percent (NNEP)	95.79%	0.41%	0.62%	1.36%	-3.67%	2.09%	-11.86%	34.69%	-6.35%	0.04%
Return On Investment Capital (ROIC_SIMPLE)	-	2.22%	-	-	-	-0.23%	-	-	-	2.90%
Cost of Revenue to Revenue	22.40%	23.47%	24.72%	22.43%	23.76%	27.87%	26.09%	22.42%	23.27%	24.52%
SG&A Expenses to Revenue	67.88%	59.12%	68.59%	59.94%	59.17%	61.60%	65.76%	58.77%	62.33%	58.31%
R&D to Revenue	8.19%	9.86%	10.41%	9.32%	9.65%	11.81%	11.65%	11.97%	8.98%	9.10%
Operating Expenses to Revenue	76.08%	68.98%	79.00%	69.26%	68.82%	73.41%	77.41%	88.25%	71.32%	67.42%
Earnings before Interest and Taxes (EBIT)	1.78	8.72	-3.98	9.77	8.08	-1.29	-3.83	-14	6.29	10
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	4.46	19	-0.05	13	12	2.92	0.14	-9.72	11	15
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.65	1.33	1.06	1.61	1.51	1.94	1.35	1.41	1.36	1.61
Price to Tangible Book Value (P/TBV)	2.06	1.63	1.30	1.94	1.81	2.31	1.60	1.68	1.60	1.91
Price to Revenue (P/Rev)	0.92	0.78	0.61	0.95	0.93	1.25	0.86	0.83	0.83	0.88
Price to Earnings (P/E)	7.18	22.67	20.73	43.37	32.12	109.21	64.46	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	13.92%	4.41%	4.82%	2.31%	3.11%	0.92%	1.55%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.61	1.37	1.05	1.54	1.57	1.93	1.38	1.39	1.36	1.65
Enterprise Value to Revenue (EV/Rev)	0.96	0.71	0.68	1.02	0.87	1.25	0.81	0.85	0.84	0.85
Enterprise Value to EBITDA (EV/EBITDA)	9.62	7.93	8.68	12.90	8.89	19.39	9.71	28.65	31.37	26.09
Enterprise Value to EBIT (EV/EBIT)	13.31	14.34	16.95	28.86	17.26	43.08	27.64	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	6.86	18.71	20.78	41.70	27.80	90.94	50.98	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	12.68	12.86	17.00	27.86	13.82	17.53	13.62	17.35	27.39	28.94
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	7.46	0.00	0.00	9.20	0.00	7.27	15.98	0.00	13.77
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.50	0.27	0.46	0.45	0.25	0.38	0.24	0.38	0.34	0.00
Long-Term Debt to Equity	0.43	0.25	0.40	0.38	0.23	0.31	0.22	0.31	0.29	0.00
Financial Leverage	0.00	-0.03	0.11	0.09	-0.02	-0.06	0.02	0.08	-0.05	-0.20
Leverage Ratio	1.86	1.76	1.74	1.72	1.73	1.67	1.67	1.67	1.64	1.44
Compound Leverage Factor	1.26	1.77	2.02	1.62	1.63	2.32	1.89	1.75	1.51	1.45
Debt to Total Capital	33.26%	21.03%	31.69%	31.10%	20.13%	27.62%	19.29%	27.46%	25.63%	0.19%
Short-Term Debt to Total Capital	4.47%	1.35%	4.45%	4.59%	1.58%	4.84%	1.59%	4.73%	4.29%	0.00%
Long-Term Debt to Total Capital	28.79%	19.69%	27.25%	26.51%	18.55%	22.78%	17.70%	22.72%	21.35%	0.19%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	31.71%
Common Equity to Total Capital	66.74%	78.97%	68.31%	68.90%	79.87%	72.38%	80.71%	72.54%	74.37%	68.10%
Debt to EBITDA	2.77	1.76	3.40	3.37	1.60	3.80	1.83	7.51	7.92	0.05
Net Debt to EBITDA	0.43	-0.81	0.92	0.91	-0.66	0.07	-0.63	0.70	0.09	-8.59
Long-Term Debt to EBITDA	2.40	1.64	2.92	2.87	1.47	3.14	1.68	6.21	6.60	0.05
Debt to NOPAT	1.97	4.14	8.14	10.89	4.99	17.84	9.63	-12.99	-10.74	-0.80
Net Debt to NOPAT	0.30	-1.90	2.19	2.93	-2.08	0.33	-3.32	-1.21	-0.12	150.80
Long-Term Debt to NOPAT	1.71	3.88	7.00	9.29	4.60	14.71	8.83	-10.75	-8.94	-0.80
Altman Z-Score	2.50	2.47	2.15	2.79	2.63	2.97	2.41	2.36	2.71	3.69
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	18.44%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.58	2.97	2.85	2.95	2.77	2.80	2.74	2.73	3.09	3.69
Quick Ratio	2.24	2.56	2.38	2.48	2.30	2.31	2.23	2.28	2.53	3.17
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-106	33	-35	-29	32	-48	39	22	-19	38
Operating Cash Flow to CapEx	52.42%	73.20%	-67.14%	115.30%	279.88%	319.31%	-457.34%	252.02%	338.46%	325.41%
Free Cash Flow to Firm to Interest Expense	-185.43	0.00	-53.35	-48.84	71.12	-96.19	75.48	35.10	-39.52	0.00
Operating Cash Flow to Interest Expense	9.53	0.00	-7.82	14.56	37.69	21.10	-19.77	7.64	18.46	0.00
Operating Cash Flow Less CapEx to Interest Expense	-8.65	0.00	-19.47	1.93	24.22	14.49	-24.09	4.61	13.01	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.12	1.01	1.05	1.01	0.98	0.95	0.96	1.00	1.00	1.01
Accounts Receivable Turnover	5.52	5.25	5.38	5.01	4.92	5.05	4.63	4.49	4.78	5.02
Inventory Turnover	4.08	4.22	4.41	4.37	4.02	4.02	4.08	4.27	4.09	4.25
Fixed Asset Turnover	5.39	4.97	4.83	4.46	4.19	3.96	3.94	4.44	4.39	4.69
Accounts Payable Turnover	3.33	3.41	3.66	3.33	3.27	3.38	4.06	3.93	4.43	3.88
Days Sales Outstanding (DSO)	66.07	69.58	67.83	72.80	74.13	72.24	78.86	81.22	76.42	72.64
Days Inventory Outstanding (DIO)	89.47	86.55	82.69	83.51	90.69	90.90	89.48	85.55	89.16	85.89
Days Payable Outstanding (DPO)	109.73	107.17	99.77	109.56	111.64	108.07	90.00	92.98	82.37	94.03
Cash Conversion Cycle (CCC)	45.82	48.96	50.76	46.75	53.18	55.07	78.34	73.80	83.22	64.50
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	276	233	297	304	248	281	255	273	280	250
Invested Capital Turnover	2.08	1.83	1.64	1.59	1.71	1.69	1.58	1.55	1.73	1.82
Increase / (Decrease) in Invested Capital	106	-26	32	35	-28	47	-41	-31	32	-31
Enterprise Value (EV)	444	320	312	469	389	542	352	380	380	411
Market Capitalization	424	352	279	436	418	540	375	371	379	424
Book Value per Share	$1.96	$2.03	$2.01	$2.07	$2.11	$2.11	$2.11	$1.99	$2.10	$1.98
Tangible Book Value per Share	$1.57	$1.65	$1.64	$1.71	$1.76	$1.77	$1.78	$1.66	$1.78	$1.67
Total Capital	384	336	386	394	347	385	344	363	375	386
Total Debt	128	71	122	122	70	106	66	100	96	0.72
Total Long-Term Debt	111	66	105	104	64	88	61	83	80	0.72
Net Debt	20	-33	33	33	-29	1.98	-23	9.25	1.09	-135
Capital Expenditures (CapEx)	10	11	7.56	7.50	5.98	3.32	2.22	1.88	2.57	3.36
Debt-free, Cash-free Net Working Capital (DFCFNWC)	50	49	69	72	51	59	61	75	82	72
Debt-free Net Working Capital (DFNWC)	158	152	158	161	150	163	150	166	177	208
Net Working Capital (NWC)	141	148	141	143	144	145	144	148	161	208
Net Nonoperating Expense (NNE)	0.10	-0.03	0.17	0.33	0.17	-0.32	-0.60	7.32	0.89	-0.03
Net Nonoperating Obligations (NNO)	20	-33	33	33	-29	1.98	-23	9.25	1.09	-135
Total Depreciation and Amortization (D&A)	2.68	10	3.92	3.46	3.77	4.21	3.97	4.20	4.40	4.45
Debt-free, Cash-free Net Working Capital to Revenue	10.88%	10.83%	14.85%	15.64%	11.30%	13.58%	13.90%	16.77%	18.10%	15.00%
Debt-free Net Working Capital to Revenue	34.20%	33.74%	34.22%	35.22%	33.31%	37.67%	34.41%	36.95%	38.96%	43.25%
Net Working Capital to Revenue	30.49%	32.73%	30.50%	31.26%	32.09%	33.37%	33.15%	33.11%	35.43%	43.25%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.06	($0.02)	$0.04	$0.02	$0.00	($0.02)	($0.13)	$0.09	$0.05
Adjusted Weighted Average Basic Shares Outstanding	130.90M	130.07M	131.08M	131.29M	131.31M	131.23M	131.86M	132.57M	132.58M	131.67M
Adjusted Diluted Earnings per Share	$0.00	$0.06	($0.02)	$0.04	$0.02	$0.00	($0.02)	($0.13)	$0.09	$0.05
Adjusted Weighted Average Diluted Shares Outstanding	132.23M	132.38M	131.08M	133.07M	133.42M	132.75M	131.86M	132.57M	133.93M	131.67M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	130.92M	131.18M	131.26M	131.31M	132.04M	131.96M	132.57M	132.58M	132.58M	126.83M
Normalized Net Operating Profit after Tax (NOPAT)	1.25	7.46	-2.80	5.64	5.64	-0.89	-2.70	3.47	4.37	7.65
Normalized NOPAT Margin	1.07%	6.45%	-2.60%	4.81%	5.19%	-0.89%	-2.45%	2.66%	3.79%	6.04%
Pre Tax Income Margin	1.04%	7.58%	-4.30%	7.82%	7.04%	-1.80%	-3.95%	-11.16%	5.06%	8.10%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	3.12	0.00	-6.13	16.45	18.20	-2.57	-7.45	-22.45	13.36	0.00
NOPAT to Interest Expense	0.55	0.00	-4.32	9.50	7.52	-1.77	-5.25	-15.68	28.06	0.00
EBIT Less CapEx to Interest Expense	-15.07	0.00	-17.78	3.83	4.73	-9.18	-11.77	-25.48	7.91	0.00
NOPAT Less CapEx to Interest Expense	-17.63	0.00	-15.97	-3.12	-5.95	-8.37	-9.57	-18.72	22.61	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2,959.23%

Frequently Asked Questions About Organogenesis' Financials

When does Organogenesis's financial year end?

According to the most recent income statement we have on file, Organogenesis' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Organogenesis' net income changed over the last 2 years?

Organogenesis' net income appears to be on a downward trend, with a most recent value of $861 thousand in 2024, falling from $15.53 million in 2022. The previous period was $4.95 million in 2023.

What is Organogenesis's operating income?

Organogenesis's total operating income in 2024 was -$1.28 million, based on the following breakdown:

Total Gross Profit: $366.30 million
Total Operating Expenses: $367.59 million

How has Organogenesis revenue changed over the last 2 years?

Over the last 2 years, Organogenesis' total revenue changed from $450.89 million in 2022 to $482.04 million in 2024, a change of 6.9%.

How much debt does Organogenesis have?

Organogenesis' total liabilities were at $112.57 million at the end of 2024, a 37.9% decrease from 2023, and a 38.7% decrease since 2022.

How much cash does Organogenesis have?

In the past 2 years, Organogenesis' cash and equivalents has ranged from $102.48 million in 2022 to $135.57 million in 2024, and is currently $135.57 million as of their latest financial filing in 2024.

How has Organogenesis' book value per share changed over the last 2 years?

Over the last 2 years, Organogenesis' book value per share changed from 2.03 in 2022 to 1.98 in 2024, a change of -2.3%.

Remove Ads

Related Companies

This page (NASDAQ:ORGO) was last updated on 4/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Organogenesis (ORGO) Financials

Frequently Asked Questions About Organogenesis' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Organogenesis (ORGO) Financials

Annual Income Statements for Organogenesis

Quarterly Income Statements for Organogenesis

Annual Cash Flow Statements for Organogenesis

Quarterly Cash Flow Statements for Organogenesis

Annual Balance Sheets for Organogenesis

Quarterly Balance Sheets for Organogenesis

Annual Metrics and Ratios for Organogenesis

Quarterly Metrics and Ratios for Organogenesis

Frequently Asked Questions About Organogenesis' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools